This series in the journal Blood outlines both current obstacles and new opportunities for the future on a selection of emerging immunotherapies now available to patients with hematologic diseases.
In the introduction to the series, Dr. Sophie Paczesny and colleagues illustrate how new immunotherapies use the patients’ own immune cells to kill cancer cells in a targeted way as compared to chemotherapies that indiscriminately kill quickly proliferating cells as well as healthy cells.
Articles in the series are:
- Chimeric antigen receptor-modified T cells
- The current status, challenges, and potential future applications of CAR T-cell therapy in hematologic malignancies
- Defining success with cellular therapeutics
- The current state of the field for clinical end point analysis comparing two prominent cellular therapies: hematopoietic cell transplantation and CAR T cells
- Vaccine therapy in hematologic malignancies
- Cancer vaccines that disrupt tumor-associated tolerance and then activate and selectively expand tumor-specific lymphocytes
- Immune regulatory cell infusion for GVHD prevention and therapy
- Exploiting regulatory cells and their molecular pathways to limit the pathogenic immune responses leading to GVHD